No new clinical data were released — the posters are trial-in-progress updates. The key catalyst to watch is the initial clinical data readout expected later in 2026. Until then, the stock is likely to trade on broader biotech sentiment and cash runway updates.
Price Chart
Executive Summary
Molecular Partners announced trial-in-progress poster presentations at ASCO and SNMMI 2026 for its lead Radio-DARPin candidate MP0712 (DLL3-targeting, 212Pb-based) in a Phase 1/2a study for small cell lung cancer and other neuroendocrine cancers. Dosing is ongoing in the first cohort, and initial clinical data are expected in 2026. The filing is a routine clinical update with no new efficacy or safety data disclosed.
Key Facts
- MP0712 is a 212Pb-based Radio-DARPin Therapy targeting DLL3, expressed in >85% of SCLC tumors.
- Phase 1/2a study (NCT07278479) is actively recruiting, dosing ongoing in first cohort.
- Initial clinical data expected in 2026.
- Co-developed with strategic partner Orano Med.
- First patient imaging/dosimetry data presented at TWC January 2026 showed specific tumor uptake.
- Trial-in-progress posters at ASCO (May 30) and SNMMI (June 2) — no new data disclosed.
Financial Impact
No financial figures disclosed. Pre-revenue clinical-stage biotech.
Risk Factors
- Phase 1/2a data may show safety or efficacy issues.
- DLL3-targeting space is competitive (e.g., Amgen's tarlatamab).
- Pre-revenue company with no near-term revenue catalyst.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003818 |
| Document: f6k_060126.htm | 0001171843-26-003818 |
| Document: 0001171843-26-003818-index-headers.html | 0001171843-26-003818 |
| Document: 0001171843-26-003818-index.html | 0001171843-26-003818 |
| Document: 0001171843-26-003818.txt | 0001171843-26-003818 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 9w ago | 6-K | $4.38 $3.99 | ▼ −8.90% | ▼ −10.15% | $3.81 (−13.01%) |
Jul 20, 2026 14w ago | 6-K | $4.00 $4.25 | ▲ +6.25% | ▲ +2.13% | $3.81 (−4.75%) |
Jul 16, 2026 14w ago | Press Release | $4.10 $4.21 | ▲ +2.68% | ▼ −0.93% | $3.81 (−7.07%) |
Jul 6, 2026 16w ago | Press Release | $4.00 $3.93 | ▼ −1.75% | ▼ −1.18% | $3.81 (−4.75%) |
Jul 2, 2026 16w ago | 6-K | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.81 (−4.27%) |
Jul 2, 2026 16w ago | Press Release | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.81 (−4.27%) |
Jun 1, 2026 21w ago | 6-K | $3.95 $3.87 | ▼ −2.03% | ▼ −0.73% | $3.81 (−3.54%) |
May 12, 2026 24w ago | 6-K | $4.00 $3.71 | ▼ −7.25% | ▼ −6.64% | $3.81 (−4.75%) |
May 1, 2026 25w ago | Press Release | $4.24 $3.95 | ▼ −6.84% | ▼ −12.12% | $3.81 (−10.14%) |
Mar 30, 2026 30w ago | 6-K | $3.93 $4.28 | ▲ +8.91% | ▼ −3.69% | $3.81 (−3.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers